PT  - JOURNAL ARTICLE
AU  - Evangelina Membriani
AU  - Erika Cuenca
AU  - Leticia Limongi
AU  - Ana Putruele
AU  - Carlos Luna
TI  - Latent tuberculosis screening and entering antibody therapy monoclonares against tumor necrosis factor
AID  - 10.1183/13993003.congress-2016.PA2701
DP  - 2016 Sep 01
TA  - European Respiratory Journal
PG  - PA2701
VI  - 48
IP  - suppl 60
4099  - http://erj.ersjournals.com/content/48/suppl_60/PA2701.short
4100  - http://erj.ersjournals.com/content/48/suppl_60/PA2701.full
SO  - Eur Respir J2016 Sep 01; 48
AB  - Patients with autoimmune diseases are at increased risk of infections including tuberculosis (TB ) .The screening and treatment of TBL is a fundamental pillar in our country yet available IGRA tests are found and there are no guidelines to assess the risk of initiating treatment in this patient group .A prospective study was performed to assess whether treatment with isoniazid and those with anti-TNF TBL provides a higher benefit to risk of hepatotoxicity and assess whether this group of patients should It is considered uniform or certain repairs should be taken in individual cases.During 18 months in an university hospital. 119 patients, 54 had TBL and start anti-TNF. 32 received isoniazid (H), 22 not received.The population was predominantly female , average age 49,5.La majority had rheumatoid arthritis. The group that received H received systemic corticosteroids associated with methotrexate mainly. The treatments were abatacept, adalimumab , etanercept and rituximab. . In the treated group two patients hepatotoxicity must discontinue the medication. During the study period no TB patients were reported in either group.Although TB cases were not recorded , there is a risk of hepatotoxicity and may be increased to the association of other potentially hepatotoxic drugs .The number of studied patients is low , further studies to establish needed if the benefit of treatment with isoniazid in patients receiving anti-TNF outweighs the risk of hepatotoxicity in our country . A custom behavior should be evaluated in patients receiving methotrexate at the time of screening of TBL .